Skip to main content
Mereo BioPharma Group plc logo

Mereo BioPharma Group plc — Investor Relations & Filings

Ticker · MREO ISIN · GB00BZ4G2K23 LEI · 213800U8JQHIJOS5AS09 US Manufacturing
Open in API
Filings indexed 635 across all filing types
Latest filing 2019-11-11 Regulatory Filings
Country GB United Kingdom
Listing US MREO

About Mereo BioPharma Group plc

https://www.mereobiopharma.com/

Mereo BioPharma Group plc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases with limited or no treatment options. The company's strategy involves acquiring and advancing promising clinical-stage product candidates that have been de-prioritized by larger pharmaceutical or biotechnology companies. This capital-efficient model allows it to develop a specialized pipeline. Its two lead programs are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat for Alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD). Mereo BioPharma also engages in strategic partnerships and out-licenses other clinical assets to deliver impactful treatments to patients.

Recent filings

Filing Released Lang Actions
Price Monitoring Extension
Regulatory Filings Classification · 98% confidence The document is a short notification from the London Stock Exchange's Regulatory News Service (RNS) regarding a 'Price Monitoring Extension' for a specific security. It does not contain financial statements, management reports, or other substantive corporate disclosures. As it is a standard regulatory notification regarding trading parameters that does not fit into specific categories like M&A, dividends, or share issues, it is classified as a general regulatory filing.
2019-11-11 English
Mereo BioPharma Phase 2b ASTEROID Study
Earnings Release Classification · 95% confidence The document is a press release from Mereo BioPharma announcing topline clinical trial results (Phase 2b ASTEROID study) for their drug setrusumab. It details study endpoints, efficacy data, safety profiles, and future development plans. This type of announcement, which provides initial highlights of financial or operational performance (in this case, clinical trial results which are material to the company's valuation), is classified as an Earnings Release (ER) or a general regulatory announcement. Given the specific focus on clinical trial data release, 'ER' is the most appropriate category for this type of material corporate disclosure. FY 2019
2019-11-11 English
Holdings in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings', which is a regulatory requirement for disclosing significant changes in share ownership (crossing thresholds). This aligns perfectly with the definition of a Major Shareholding Notification (MRQ).
2019-10-18 English
Holdings in Company
Major Shareholding Notification Classification · 100% confidence The document is a 'TR-1: Standard form for notification of major holdings'. It explicitly details a change in voting rights/shareholding percentage (from 27.56% to 8.00%) by Woodford Investment Management Ltd in Mereo BioPharma Group plc. This falls directly under the definition of a Major Shareholding Notification (MRQ).
2019-10-17 English
Notification of Director Dealing
Director's Dealing Classification · 100% confidence The document is a formal notification of a share purchase by a company director (Peter Fellner, Chairman of the Board). It explicitly uses the title 'Notification of Director Dealing' and provides the required disclosure details under the EU Market Abuse Regulation, including the name of the person discharging managerial responsibilities, the nature of the transaction, and the volume/price of shares purchased. This fits the definition of a Director's Dealing (DIRS) filing.
2019-10-14 English
FORM 6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K, which is a report of a foreign private issuer submitted to the SEC under the Securities Exchange Act of 1934. It includes a press release as an exhibit dated October 7, 2019. The document is short (1361 characters) and primarily serves as a regulatory filing to report information between annual reports (20-F). It does not contain detailed financial statements or substantive financial data itself, but rather serves as a notification or update. Therefore, it fits best under the Regulatory Filings (RNS) category, which is the fallback for miscellaneous filings that do not fit other specific categories.
2019-10-07 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.